Mylan (MYL) Earns “Hold” Rating from Mizuho

Share on StockTwits

Mizuho reiterated their hold rating on shares of Mylan (NASDAQ:MYL) in a research note issued to investors on Tuesday morning, TipRanks reports.

Several other equities research analysts have also commented on MYL. Zacks Investment Research raised shares of Mylan from a hold rating to a strong-buy rating and set a $34.00 price target for the company in a report on Monday, January 21st. UBS Group lowered shares of Mylan from a buy rating to a neutral rating and cut their price target for the stock from $54.00 to $32.00 in a report on Wednesday, January 23rd. Credit Suisse Group reissued a buy rating and issued a $37.00 price target on shares of Mylan in a report on Wednesday, March 6th. Morgan Stanley raised shares of Mylan from an equal weight rating to an overweight rating and set a $35.00 price target for the company in a report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, SunTrust Banks started coverage on shares of Mylan in a report on Tuesday, March 19th. They issued a buy rating and a $35.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $37.35.

Shares of NASDAQ:MYL traded down $0.32 during trading on Tuesday, hitting $19.89. 138,116 shares of the stock traded hands, compared to its average volume of 9,187,441. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.51 and a quick ratio of 0.85. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of 4.38, a price-to-earnings-growth ratio of 1.04 and a beta of 1.44. Mylan has a 52-week low of $19.40 and a 52-week high of $42.50.

Mylan (NASDAQ:MYL) last posted its earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.03. The firm had revenue of $2.50 billion during the quarter, compared to analyst estimates of $2.70 billion. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.96 EPS. On average, sell-side analysts anticipate that Mylan will post 4.28 earnings per share for the current fiscal year.

In other Mylan news, insider Paul Campbell sold 11,533 shares of Mylan stock in a transaction on Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.81% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC boosted its stake in Mylan by 107.1% during the 1st quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock worth $27,000 after purchasing an additional 500 shares during the last quarter. Pinnacle Bank boosted its stake in Mylan by 66.4% during the 1st quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock worth $30,000 after purchasing an additional 423 shares during the last quarter. Cresset Asset Management LLC acquired a new stake in Mylan during the 1st quarter worth $41,000. Mascoma Wealth Management LLC acquired a new stake in Mylan during the 1st quarter worth $47,000. Finally, Kinneret Advisory LLC acquired a new stake in Mylan during the 4th quarter worth $71,000. 83.69% of the stock is currently owned by institutional investors.

Mylan Company Profile

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.

Featured Story: Diluted Earnings Per Share

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report